Immatics NV美股招股说明书(2025-12-05版)

Ordinary Shares We are offeringordinary shares, nominal value€0.01 per share. The public offering price is $ordinary share. Our ordinary shares are listed on The Nasdaq Stock Market LLC (“Nasdaq”) under the symbol “IMTX.” OnDecember4, 2025, the last reported sale price of our ordinary shares on Nasdaq was $11.87 per share. Investing in our securities involves a high degree of risk. See the “Risk Factors” section beginning onpageS-6 of this prospectus supplement and any risk factors in our Securities and Exchange Commission(“SEC”) filings that are incorporated by reference in this prospectus supplement. Neither the Securities and Exchange Commission nor any state securities commission has approved ordisapproved of these securities or determined if this prospectus supplement or the accompanyingprospectus is truthful or complete. Any representation to the contrary is a criminal offense. The securities are expected to be delivered to purchasers on or about Jefferies Cantor Table of Contents ABOUT THIS PROSPECTUS SUPPLEMENT This document consists of two parts. The first part is this prospectus supplement, which describes the specific terms of this offering. The secondpart is the accompanying prospectus, which is part of a registration statement that we filed with the SEC using a “shelf” registration process. Theaccompanying prospectus describes the general terms of the securities that may be offered pursuant to the accompanying prospectus and thegeneral manner in which those securities will be offered, some of which may not apply to this offering. This prospectus supplement and the Before buying any of the securities offered by this prospectus supplement, you should carefully read both this prospectus supplement and theaccompanying prospectus, together with all of the information incorporated by reference in this prospectus supplement, as well as the additionalinformation described under the heading “Where You Can Find More Information” and “Information Incorporated by Reference.” These documentscontain important information that you should consider when making your investment decision. We have filed or incorporated by reference To the extent there is a conflict between the information contained in this prospectus supplement, on the one hand, and the information containedin the accompanying prospectus or in any document incorporated by reference in this prospectus supplement, on the other hand, you should relyon the information in this prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement inanother document having a later date—for example, a document incorporated by reference in this prospectus supplement—the statement in the The information contained in this prospectus supplement, the accompanying prospectus or any document incorporated by reference in thisprospectus supplement is accurate only as of their respective dates, regardless of the time of delivery of this prospectus supplement, theaccompanying prospectus or the documents incorporated by reference in this prospectus supplement or in the accompanying prospectus or thesale of any securities. Our business, financial condition, results of operations and prospects may have changed materially since those dates. Neither we nor the underwriters have authorized anyone to provide you with information that is different from that contained or incorporated byreference in this prospectus supplement, the accompanying prospectus, or any free writing prospectus we may authorize to be delivered or madeavailable to you. Neither we nor the underwriters take responsibility for, or provide assurance as to the reliability of, any other information thatothers may give you. This prospectus supplement does not constitute an offer to sell or the solicitation of an offer to buy any securities other than For investors outside the United States: Neither we nor the underwriters have taken any action that would permit the offering or possession ordistribution of this prospectus supplement in any jurisdiction where action for that purpose is required, other than in the United States. Personsoutside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions Unless otherwise indicated or the context otherwise requires, (i)all references to the “company,” “we,” “our” or “us” or similar terms refer toImmatics N.V., together with its subsidiaries, including Immatics Biotechnologies GmbH and Immatics US, Inc., and (ii)references to “Immatics”refer solely to Immatics N.V. Immatics N.V. is a Dutch public limited liability company (naamloze vennootschap) incorporated on March10, 2020and the holding company of Immatics Biotechnologies GmbH, a German biopharmaceutical company incorporated in 2000 focused on thedevelopment of T cell receptor-based immunotherapies for the treatment of cancer. Immatics Biotechnologies GmbH holds all material assets and